An experimental Parkinson’s drug missed its primary goal in a mid-stage trial, Roche said, in what is the second setback this week for candidate treatments for the neurodegenerative condition.
Related Posts
China Vanke Expects to Post Losses in First Half
China Vanke expects to report a loss in the first half as the continuing crisis in the country’s real-estate sector continues to weigh on developers.
McDonald’s Had a Problem With Flagging Sales. Now It’s Facing a Food-Safety Crisis.
The CDC is investigating an E. coli outbreak across 10 states linked to the burger chain, with one death and dozens of illnesses reported.
Nippon Life in Talks to Acquire Resolution Life
The potential deal follows Nippon Life’s purchase of a stake in Corebridge Financial from American International Group and underscores the Japanese insurer’s thirst for deals […]